Evidence map›Paper›PMID 41390597›Full record

ArticleScientific reports2025

E2F1-mediated PKMYT1 upregulation promotes prostate cancer progression by inhibiting the PPAR signaling pathway.

Zengshun Kou, Yu Wang, Jiaxi Zhu, Shuaizhi Zhu, Zi'ang Si, Hai Zhu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zengshun KouDepartment of Urology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Yu WangDepartment of Emergency, Qingdao Municipal Hospital, Qingdao, China.
Jiaxi ZhuLife Sciences, Faculty of Arts & Science, University of Toronto - St. George Campus, Toronto, Canada.
Shuaizhi ZhuDepartment of Urology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Zi'ang SiDepartment of Urology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Hai ZhuDepartment of Urology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. shijingzhou@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein kinase membrane associated tyrosine/threonine 1 (PKMYT1) is a protein-coding gene associated with cell cycle regulation and cancer development, but its specific mechanism in prostate cancer (PCa) has not been clarified. This study sought to elucidate the role of PKMYT1 in PCa. Expression patterns, prognostic significance and potential mechanisms of PKMYT1 were explored by the TCGA database. Single-cell sequencing was performed using the GSE137829 dataset. Multi-database prediction identified potential transcription factors regulating PKMYT1 expression. PC3 cell line with PKMYT1 knockdown was established. Functional analyses (CCK-8, Wound healing, and Transwell assays) were performed to investigate the changes in tumor malignant behavior after PKMYT1 silencing. Western blot experiments were performed to analyze the effects of PKMYT1 on epithelial-mesenchymal transition (EMT) and PPAR signaling pathway. PKMYT1 was overexpressed in prostate cancer samples and its high expression was significantly associated with poor prognosis and Th2 cell infiltration. Knockdown of PKMYT1 could effectively inhibit the proliferation, migration, and EMT process of PCa cells. Mechanistically, E2F1 is an important factor regulating PKMYT1 expression, and PKMYT1 could inhibit the activity of the PPAR signaling pathway, thus ensuring the reinforcement of PCa progression. PKMYT1 can accelerate the progression of PCa by regulating the cell cycle, EMT process and PPAR signaling pathway. Targeting PKMYT1 provide a new perspective for the treatment of prostate cancer.

Indexed as

E2F1 Transcription FactorMembrane ProteinsPeroxisome Proliferator-Activated ReceptorsProstatic NeoplasmsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesSignal TransductionAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMaleE2F1 protein, humanE2F1 Transcription FactorMembrane ProteinsPeroxisome Proliferator-Activated ReceptorsPKMYT1 protein, humanProtein Serine-Threonine KinasesProtein-Tyrosine KinasesE2F1PKMYT1PPAR signaling pathwayProstate cancerTumor treatment

Identifiers

PMID41390597
PMCPMC12820241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.